Hiroki Ikezawa

A Phase II Study of the Safety and Efficacy of Lenvatinib in Patients with Advanced Thyroid Cancer

Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki et al. · Future Oncology · 2019 · 140 citations · Full text

Medicine, Oncology, Pharmacology +16

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori et al. · Clinical Cancer Research · 2021 · 99 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

Makoto Ueno, Masafumi Ikeda, Takashi Sasaki et al. · BMC Cancer · 2020 · 95 citations · Full text

Medicine, Oncology, Pharmacology +13

A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.

Masatoshi Kudo, Masafumi Ikeda, Kenta Motomura et al. · Journal of Clinical Oncology · 2020 · 94 citations

Medicine, Oncology, Pharmacology +17

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng et al. · Clinical Cancer Research · 2021 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17